Showing results (1-10 of 440) with videos related to

Sort By:
Pageof 44
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 16, 2011
[Chemotherapy-induced stomatitis and diarrhea]Shigenori Kadowaki, Kensei Yamaguchi
International Journal of Clinical Oncology|October 18, 2017
First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intakeHiroki Hara, Shigenori Kadowaki, Masako Asayama, et al.
World Journal of Gastroenterology|January 30, 2015
Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancerShigenori Kadowaki, Miho Kakuta, Shuhei Takahashi, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 20, 2007
[The palliative care in the clinical oncology]Shigenori Kadowaki, Makoto Tahara, Nagahiro Saijo
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 1, 2004
[Early onset invasive pulmonary zygomycosis following allogeneic peripheral blood stem cell transplantation in a patient with therapy-related myelodysplastic syndrome]Keiki Kawakami, Yasuyuki Watanabe, Shigenori Kadowaki
Therapeutic Advances in Medical Oncology|March 14, 2022
The dawn of precision medicine in diffuse-type gastric cancerAkira Ooki, Kensei Yamaguchi
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 16, 2021
The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberrationAkira Ooki, Kensei Yamaguchi
International Journal of Clinical Oncology|April 8, 2024
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumabTakeru Wakatsuki, Naoki Ishizuka, Shuichi Hironaka, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 studyKohei Shitara, Hiroji Iwata, Shunji Takahashi, et al.
Oncology Letters|August 8, 2017
Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancerYukiya Narita, Shigenori Kadowaki, Toshiki Masuishi, et al.
Pageof 44